{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:26:43Z","timestamp":1790670403428,"version":"4.1.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 1999 a working group of the World Health Organization (WHO) published a revised classification for myelodysplastic syndromes (MDS): RA, RARS, refractory cytopenia with multilineage dysplasia (RC+Dys), RAEB I and II, del (5q) syndrome, and MDS unclassifiable. Chronic myelomonocytic leukemia (CMML) and RAEB-t were excluded. Standard French-American-British (FAB) and new WHO classifications have been compared in a series of patients (n\u2009=\u2009431) from a single center, analyzing morphologic, clinical, and cytogenetic data. According to the WHO findings, dysgranulocytopoiesis or dysmegakaryocytopoiesis only were found in 26% of patients with less than 5% medullary blasts. These patients are thus unclassified and should remain in the subgroups RA and RARS. Splitting of heterogeneous RAEB into 2 subgroups according to blast count was supported by a trend to a statistically significant difference in the single-center study population. Patients with CMML whose white blood cell counts are above 13\u2009000\/\u03bcL may be excluded from the MDS classification, as warranted by WHO, but a redistribution of patients with dysplastic CMML according to medullary blast count leads to more heterogeneity in other WHO subgroups. Although the natural courses of RAEB-T and acute myeloid leukemia (AML) with dysplasia are different, comparable median survival durations after treatment in patients with RAEB-T and AML were in favor of the proposed 20% medullary blast threshold for AML. The homogeneity of subgroups was studied by evaluating prognostic scores. A significant shift into lower IPSS risk groups was evident in the new classification. These data cannot provide evidence for the new WHO proposal, which should not be adopted for routine clinical use at present. Some of its aspects can provide a starting point for further studies involving refined cytogenetics and clinical results.<\/jats:p>","DOI":"10.1182\/blood.v98.10.2935","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T12:46:47Z","timestamp":1027774007000},"page":"2935-2941","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":93,"title":["Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution"],"prefix":"10.1182","volume":"98","author":[{"given":"Thomas","family":"No\u0308sslinger","sequence":"first","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Reisner","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Koller","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Gru\u0308ner","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Tu\u0308chler","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadwiga","family":"Nowotny","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Pittermann","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pfeilsto\u0308cker","sequence":"additional","affiliation":[{"name":"From the Third Medical Department for Hematology and Oncology and the Ludwig Boltzmann Institute for Leukemia Research and Hematology, Hanusch Hospital, Vienna, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021219013817200_B1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes.","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B2","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1365-2141.1995.tb05356.x","article-title":"Hypocellular myelodysplastic syndromes (MDS): new proposals.","volume":"91","author":"Tuzuner","year":"1995","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF01696227","article-title":"FAB classification of myelodysplastic syndromes: merits and controversies.","volume":"71","author":"Verhoef","year":"1995","journal-title":"Ann Hematol."},{"key":"2020021219013817200_B4","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10428199309148501","article-title":"Chronic myelomonocytic leukemia (CMML): a myelodysplastic or myeloproliferative syndrome?","volume":"9","author":"Michaux","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"2020021219013817200_B5","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukemia. Proposals by the French-American-British Cooperative leukaemia group.","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML-dysplastic versus proliferative type.","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res."},{"key":"2020021219013817200_B7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/10428199509051706","article-title":"The contribution of Auer rods to the classification and prognosis of myelodysplastic syndromes.","volume":"17","author":"Seymour","year":"1995","journal-title":"Leuk Lymphoma."},{"key":"2020021219013817200_B8","first-page":"169","article-title":"RAEB-T: a heterogenous entity [abstract]?","volume":"23","author":"Germing","year":"1999","journal-title":"Leuk Res."},{"key":"2020021219013817200_B9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1990.tb02536.x","article-title":"Two types of acquired idiopathic sideroblastic anaemia (AISA).","volume":"74","author":"Gattermann","year":"1990","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B10","first-page":"67","article-title":"Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype [abstract].","volume":"62","author":"Michels","year":"1990","journal-title":"Lab Invest."},{"key":"2020021219013817200_B11","first-page":"20","article-title":"Refractory cytopenia with multilineage dysplasia: further characterization of an \u2018unclassifiable\u2019 myelodysplastic syndrome.","volume":"10","author":"Rosati","year":"1996","journal-title":"Leukemia."},{"key":"2020021219013817200_B12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/sj.leu.2400966","article-title":"Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia.","volume":"12","author":"Matsuda","year":"1998","journal-title":"Leukemia."},{"key":"2020021219013817200_B13","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting\u2014Airlie House, Virginia, November 1997.","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol."},{"key":"2020021219013817200_B14","first-page":"1","article-title":"Counterstained enhanced chromosome binding.","volume":"57","author":"Schweizer","year":"1981","journal-title":"Hum Genet."},{"key":"2020021219013817200_B15","volume-title":"ISCN: an International System for Human Cytogenetic Nomenclature.","author":"Mitelman","year":"1995"},{"key":"2020021219013817200_B16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"2020021219013817200_B17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1365-2141.1999.01559.x","article-title":"Cross-validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics.","volume":"106","author":"Pfeilsto\u0308cker","year":"1999","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc."},{"key":"2020021219013817200_B19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables.","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc."},{"key":"2020021219013817200_B20","first-page":"131","article-title":"The World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes.","volume":"72","author":"Bennett","year":"2000","journal-title":"Int J Hematol."},{"key":"2020021219013817200_B21","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","article-title":"Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.","volume":"24","author":"Germing","year":"2000","journal-title":"Leuk Res."},{"key":"2020021219013817200_B22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood.V74.1.395.395","article-title":"Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients.","volume":"74","author":"Sanz","year":"1989","journal-title":"Blood."},{"key":"2020021219013817200_B23","first-page":"1315","article-title":"Cytogenetic analysis has strong prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.","volume":"7","author":"Morel","year":"1993","journal-title":"Leukemia."},{"key":"2020021219013817200_B24","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0145-2126(01)00014-5","article-title":"Dysplastic versus proliferative CMML\u2014a retrospective analysis of 91 patients from a single institution.","volume":"25","author":"No\u0308sslinger","year":"2001","journal-title":"Leuk Res."},{"key":"2020021219013817200_B25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.1996.14.9.2486","article-title":"Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study.","volume":"14","author":"Bernstein","year":"1996","journal-title":"J Clin Oncol."},{"key":"2020021219013817200_B26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/10428199609054828","article-title":"Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes.","volume":"23","author":"Jotterand","year":"1996","journal-title":"Leuk Lymphoma."},{"key":"2020021219013817200_B27","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-2141.2000.01868.x","article-title":"Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes: Grupo Cooperativo Espanol de Citogenetica Hematologica.","volume":"108","author":"Sole","year":"2000","journal-title":"Br J Haematol."},{"key":"2020021219013817200_B28","doi-asserted-by":"crossref","first-page":"194200","DOI":"10.1002\/ajh.2830490304","article-title":"Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.","volume":"49","author":"Lewis","year":"1995","journal-title":"Am J Hematol."},{"key":"2020021219013817200_B29","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1182\/blood.V81.4.1040.1040","article-title":"The 5q syndrome: a single-institution study of 43 consecutive patients.","volume":"81","author":"Mathew","year":"1993","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2935\/1678250\/h8220102935.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/98\/10\/2935\/1678250\/h8220102935.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:12:28Z","timestamp":1733703148000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/98\/10\/2935\/52980\/Myelodysplastic-syndromes-from"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11,15]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v98.10.2935","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11,15]]}}}